PointState Capital LP Makes New Investment in Caris Life Sciences, Inc. $CAI

Posted by Francis Steltz on Aug 27th, 2026

PointState Capital LP bought a new stake in Caris Life Sciences, Inc. (NASDAQ:CAI – Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 6,828,835 shares of the company’s stock, valued at approximately $121,690,000. Caris Life Sciences makes up approximately 1.6% of PointState Capital LP’s investment portfolio, making the stock its 22nd largest position.

Other institutional investors and hedge funds have also modified their holdings of the company. Bank of America Corp DE purchased a new stake in Caris Life Sciences in the 2nd quarter worth about $21,395,000. Freestone Grove Partners LP purchased a new position in Caris Life Sciences during the 2nd quarter valued at about $65,000. PDT Partners LLC acquired a new position in shares of Caris Life Sciences in the 2nd quarter valued at about $392,000. Canada Pension Plan Investment Board purchased a new stake in shares of Caris Life Sciences in the second quarter worth approximately $24,502,000. Finally, Legal & General Group Plc acquired a new stake in shares of Caris Life Sciences during the second quarter worth approximately $571,000.

Caris Life Sciences Trading Down 4.2%

Shares of NASDAQ:CAI opened at $26.82 on Thursday. The company has a current ratio of 5.53, a quick ratio of 4.88 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $7.58 billion, a PE ratio of 74.50 and a beta of 0.68. Caris Life Sciences, Inc. has a 1 year low of $14.19 and a 1 year high of $39.18. The firm has a fifty day moving average price of $18.97 and a 200 day moving average price of $18.64.

Caris Life Sciences declared that its board has approved a share repurchase program on Monday, June 8th that allows the company to repurchase $100.00 million in outstanding shares. This repurchase authorization allows the company to purchase up to 2.1% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s board believes its stock is undervalued.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on CAI shares. Citigroup cut their target price on shares of Caris Life Sciences from $35.00 to $28.00 and set a “buy” rating for the company in a research report on Friday, May 8th. JPMorgan Chase & Co. dropped their price target on shares of Caris Life Sciences from $35.00 to $30.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. New Street Research assumed coverage on Caris Life Sciences in a research report on Friday, May 8th. They set a “market perform” rating for the company. Evercore restated an “outperform” rating and issued a $26.00 target price on shares of Caris Life Sciences in a research note on Thursday, August 6th. Finally, Robert W. Baird set a $22.00 target price on Caris Life Sciences in a research report on Friday, May 8th. Seven analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $26.33.

View Our Latest Analysis on Caris Life Sciences

Caris Life Sciences Company Profile

(Free Report)

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.